MedTrace Logo

D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia

NCT04584580 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-10-14

No results posted yet for this study

Summary

evaluation of the efficacy and safety of D-dimer adjusted heparin versus therapeutic dose heparin in patients with COVID-19 Pneumonia.

Conditions

  • Coronavirus Disease (COVID)19

Interventions

DRUG

low-molecular-weight heparin

low-molecular-weight heparin administered via subcutaneous injection

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Ashraf Madkour · Ain Shams University, Faculty of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2020-10-31
Completion
2020-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04584580 on ClinicalTrials.gov